Symposium – Fonds HIV Ontrafelen

Every year in September, the HIV Cure Research Center organized a lively HIV-oriented symposium in the picturesque city of Ghent, Belgium. Since the pandemic outbreak of SARS-CoV-2 in 2020, the lab has also invested heavily in the initiation of key research in COVID-19. Therefore, for the second year in a row, we decided to organize an HIV and SARS-CoV-2 hybrid symposium. During this symposium we discussed key aspects of SARS-CoV-2 pathogenesis and HIV cure. You can now relive the symposium online!

Program

	COVID-19 PATHOGENESIS - Chaired by Steven Callens & Guido Vanham
09.00 - 09.05	Welcome and Introduction Linos Vandekerckhove, Ghent University Hospital, Ghent, Belgium
09.05 - 09.30	COVID-19 pandemic: a tale of a bat virus from China that changed Belgian history Steven Van Gucht, Sciensano, Brussels, Belgium Q&A
09.30 - 09.55	SARS-CoV-2 spread through the human body Jolien Van Cleemput, Ghent University, Ghent, Belgium Q&A
09.55 - 10.20	Poster Session 1. External validation of 10 clinical scores for prediction of mechanical ventilation and 90-day mortality in patients admitted with COVID-19 Gil Verschelden, CUB and ULB, Brussels, Belgium 2. TGF-β2 is associated with asymptomatic/mild SARS-CoV-2 infection during pregnancy Susan Pereira Ribeiro, Emory University, Atlanta, GA, USA 3. Artificial intelligence predicts severity of COVID-19 based on correlation of exaggerated monocyte activation, excessive organ damage and hyperinflammatory syndrome Olga Vershinina, Lobachevsky University, Nizhniy Novgorod, Russia 4. Novel CRISPR-Cas13d system to target highly conserved sequences of SARS-CoV-2 and other human coronaviruses Mouraya Hussein, University of Amsterdam, Amsterdam, The Netherlands 5. Investigation of nosocomial outbreaks of SARS-CoV-2 at a University Hospital using whole genome sequencing Laurens Lambrechts, Ghent University, Ghent, Belgium
10.20 - 10.45	Break

	COVID-19 VACCINATION - Chaired by Sarah Gerlo & Bert Schepens
10.45 - 11.10	Response of SARS-CoV-2 vaccination towards variants Steven Callens, Ghent University Hospital, Ghent, Belgium Q&A
11.10 - 11.35	Antibody-based treatments to prevent and tackle SARS-CoV-2 infections Delphine Acar, Ghent University Hospital, Ghent, Belgium Q&A
11.35 - 12.00	Poster Session 1. COVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies Jozefien Declercq, Ghent University and VIB, Ghent, Belgium 2. COVID-19 transmission within a cluster of Belgian students: epidemiological and clinical characteristics and their implications on future response and vaccination strategies Febe Magherman & Aron Walraevens , Ghent University, Ghent, Belgium 3. The Neutralizing Activity of convalescent plasma from patients infected with the B.1 SARS-CoV-2 strain drops against the Beta variant and is highly diverse against the other Variants of Concern Danielle Perez Bercoff, Luxembourg Institute of Health, Luxembourg 4. Comparing anti-S1 antibody titers in cancer patients after BNT162B2 or ChAdOx1 COVID-19 vaccination Yana Debie, University Hospital Antwerp, Edegem, Belgium
12.00 - 13.00	Lunch/Satellite Symposia

	HIV RESERVOIR - Chaired by Jozefien De Clerq & Marion Pardons
13.00 - 13.25	Spatial Approaches to Identify and Characterize HIV Reservoirs Jacob Estes, Oregon Health and Science University, Oregon, US Q&A
13.25 - 13.50	Next generation multiplex assays for assessement of HIV intactness Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium Q&A
13.50 - 14.15	Poster Session 1. Dynamics of inflammatory mediators and their clinical correlates following early treated acute HIV infection Jozefien De Clercq, Ghent University and Ghent University Hospital, Ghent, Belgium 2. Multiplex assays in dPCR for the quantification of the HIV-1 reservoir Willem Van Snippenberg, Ghent University, Ghent, Belgium 3. Chimeric proviral/human transcription events at the bach2 integration locus in cellular models for chronic HIV infection Ulrike Lange, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
14.15 - 14.30	Break

	HIV CURE - Chaired by Wojciech Witkowski & Jolien Van Cleemput
14.30 - 14.55	The use of bNAbs towards an HIV cure Sarah Fidler, Imperial College London, London, UK Q&A
14.55 - 15.20	Engineering the immune system for HIV Cure Paula Cannon, University of Southern California, California, US Q&A
15.20 - 15.45	Poster Session 1. Novel NK activating multimeric immunotherapeutic compleXes (NaMix) induce cytotoxic activity against HIV-1 infected cells in vitro and in vivo Carole Devaux, Luxembourg Institute of Heatlh, Esch-sur Alzette, Luxembourg 2. HYBRID CAR-T cell secreted antibodies neutralize HIV Wojciech Witkowski, Ghent University, Ghent, Belgium 3. Real-life patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens Sophie Degroote, Ghent University Hospital, Ghent, Belgium
15.45 - 16.00	Closing words Linos Vandekerckhove, Ghent University and Ghent University Hospital, Ghent, Belgium
16.00 - 17.30	Reception

WERELDWIJD LEVEN 37 MILJOEN MENSEN MET HIV. STEUN HET FONDS HIV ONTRAFELEN en Help hen.

Door de COVID-19 maatregelen zal de 7de editie pas in december 2021 plaatsvinden.

Doneren

Doneer hier!

Sponsored by:

Program

Doneren

Contact

© All rights reserved